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Abstract
Complement activation plays a critical role in controlling inflammatory responses. To assess the role of comple-
ment during ovarian cancer progression, we crossed two strains of mice with genetic complement deficiencies with
transgenic mice that develop epithelial ovarian cancer (TgMISIIR-TAg). TgMISIIR-TAg mice fully or partially deficient
for complement factor 3 (C3) (Tg+C3KO and Tg+C3HET, respectively) or fully deficient for complement factor C5a
receptor (C5aR) (Tg+C5aRKO) develop either no ovarian tumors or tumors that were small and poorly vascularized
compared to wild-type littermates (Tg+C3WT, Tg+C5aRWT). The percentage of tumor infiltrating immune cells in
Tg+C3HET tumors compared to Tg+C3WT controls was either similar (macrophages, B cells, myeloid-derived sup-
pressor cells), elevated (effector T cells), or decreased (regulatory T cells). Regardless of these ratios, cytokine pro-
duction by immune cells taken from Tg+C3HET tumors was reduced on stimulation compared to Tg+C3WT controls.
Interestingly, CD31+ endothelial cell (EC) function in angiogenesis was significantly impaired in both C3KO and C5aRKO
mice. Further, using the C5aR antagonist PMX53, tube formation of ECs was shown to be C5a-dependent, pos-
sibly through interactions with the VEGF165 but not VEGF121 isoform. Finally, the mouse VEGF164 transcript was
underexpressed in C3KO livers compare to C3WT livers. Thus, we conclude that complement inhibition blocks tumor
outgrowth by altering EC function and VEGF165 expression.
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Introduction
Tumor development is a multistep process of cumulative genetic
alterations that lead to cell autonomy. Inflammatory mechanisms are
thought to play a critical role in this process [1,2]. Lung, skin, gastro-
intestinal, liver, urinary, cervical, and ovarian cancers are all associated
with chronic inflammation, and attenuating such inflammation has
proved beneficial in the clinical setting [3–5]. Epithelial ovarian can-
cer (EOC), the fifth leading cause of cancer death among women in
the United States, is also intimately related to inflammation. Inces-
sant ovulation, a purported cause of malignant transformation in the
ovarian surface epithelium, is associated with the activation of cyto-
kine networks and repair mechanisms in ovarian stroma, whereas
pelvic inflammatory conditions, including endometriosis, predict an
increased risk of ovarian cancer [6,7]. An early increase in serum in-
flammatory cytokines is detected in ovarian cancer patients [8], and
ovarian tumors and ascites are characterized by a brisk inflammatory
milieu [9–11]. Finally, elevated levels of complement anaphylatoxins
suggestive of local complement activation have been observed in
ovarian cancer patients’ ascites [12]. The complement system is com-
prised of serum proteins, membrane-bound receptors, and regulatory
proteins [13,14]. Its effector functions in host defense and inflam-
mation are mediated mainly through the sequential activation and
proteolytic cleavage of a series of serum proteins. Complement activa-
tion occurs through three distinct activation routes, the alternative,
classic, and lectin pathways, all of which converge at a critical step:
the activation of complement factor 3 (C3) by C3 convertase-mediated
cleavage [14]. Complement functions include pathogen opsonization,
inflammation mediated by C3a and C5a complement anaphylatoxins,
and cytolysis resulting from the assembly of the membrane attack
complex on targeted cells. Eliminating C3 prevents complement
cascade activation and the generation of complement effectors that
mediate a wide array of functions [13–15]. We demonstrated a role
for complement activation in promoting the growth of transplanted
tumors through myeloid-derived suppressor cell (MDSC) recruit-
ment and activation in mice [16], but the role of complement in early
oncogenic events remains unknown.
Complement proteins are well established as important effectors
in pathologic neovascularization in age-related macular degeneration
(AMD [17]), diabetic retinopathy, and retinopathy of prematurity
[18], as well as in the regulation of the angiogenic factors required
for normal placental development [19,20]. AMD involves a process
whereby inappropriate angiogenesis in the choroid causes vascular
invasion into the adjacent retina (choroidal neovascularization); pre-
clinical models of AMD directly link complement to this process
as complement components C3a and C5a promote choroidal neo-
vascularization [21] and C5a increases vascular endothelial growth
factor (VEGF) secretion of human retinal pigment epithelial cells [17].
Neovascularization is also a critical contributor to solid tumor progres-
sion, including cases of ovarian cancer [22]. VEGF, first identified as
a vascular permeability factor secreted by tumor cells [23], plays a prin-
cipal role in angiogenesis by stimulating migration and proliferation
of endothelial cells (ECs) and the expression of angiogenesis-related
genes in ECs. Alternative splicing of the VEGF gene gives rise to mul-
tiple isoforms, including 121, 165, 189, and 206 amino acid long
products that are differentially expressed in a variety of human tissues
and tumors [24,25]. Individual VEGF isoforms may differentially con-
tribute to tumor vascularization according to the gradient model of
Grunstein et al. [26] with VEGF120 (VEGF121 mouse homologue)
recruiting peripheral vessels, VEGF188 (VEGF189 mouse homologue)
promoting tumor neo-angiogenesis, and VEGF164 (VEGF165 mouse
homologue) affecting intermediate structures. The importance of VEGF
in tumor-associated angiogenesis is well established: overexpression of
membrane-boundVEGF121 andVEGF165was linked to tumor-associated
intracerebral hemorrhage [27–29]; in a breast cancer xenograft model,
VEGF121 was described as the most potent tumor angiogenic factor;
and soluble VEGF189 expression in human colon, renal, and lung cancers
was strongly associated with increased microvessels, cancer metastasis,
and poor prognosis [30,31]. Notably, high levels of VEGF165 have
been associated with reduced survival in ovarian cancer [32], and a
phase 3 clinical trial showed that Bevacizumab, a humanized mono-
clonal antibody (mAb) that inhibits VEGF-A, improves progression-
free survival in women with ovarian cancer [33]. Although both
complement activation and neo-angiogenesis play critical roles for
ovarian cancer development, direct effects of complement activation
on tumor neo-angiogenesis remain poorly understood.
To address this gap in knowledge, we crossed C3-deficient (C3KO)
mice [34] or complement factor 5a receptor–deficient (C5aRKO) mice
[35] with C57BL/6 TgMISIIR-TAg transgenic mice that spontane-
ously develop EOC [36–38]. The immediate-early region of the SV40
virus that contains the oncogenic large and small T-antigen genes (TAg
and tag, respectively) has been extensively used in the development of
transgenic mouse models of cancer [39–42]. SV40-TAg models have
revealed much about tumor biology, permitting significant advance-
ments in the understanding of the “angiogenic switch” [43–45] and
tumor progression and invasion [46]. Expression of TAg results in the
functional inactivation of the critical tumor suppressor proteins p53
and Rb. In fact, mutation and/or loss of TP53 is the most frequent
genetic alteration identified in EOC, particularly the serous subtype
[47,48], and mutation and/or loss of Rb and its downstream signaling
mediators is also common [36,37,49,50]. Consistent with this fact, the
expression of SV40 under the transcriptional control of the Müllerian
inhibiting substance type II receptor (MISIIR) gene promoter triggers
spontaneous ovarian cancer development in transgenic mice. SV40
TAg–induced ovarian cancer closely resembles the histotype of serous
EOC, the most common EOC histotype in humans [36]. We report
that C3 and C5aR deficiencies resulted in profoundly impaired EOC
growth, reduced tumor vascularization, and inhibition of specific
VEGF isoforms, revealing a novel mechanism of VEGF regulation by
complement anaphylatoxin C5a.
Materials and Methods
Mice
All mouse experiments were approved by the Institutional Ani-
mal Care and Use Committee of the University of Pennsylvania and
conducted according to guidelines of the National Institutes of Health.
C57BL/6 TgMISIIR-TAg transgenic mice [36], C3KO (B6.129S4-
C3tm1Crr/J) mice [34], and C5aRKO (C5ar1tm1Cge/J) mice [35] have
been described. Mice were housed in a barrier animal facility of the
University of Pennsylvania on a 12-hour light/dark cycle. Water and
standard rodent diet were provided ad libitum.
C57BL/6 TgMISIIR-TAg mice develop spontaneous bilateral
serous ovarian tumors and have a mean life expectancy of 151.6 days
(∼22 weeks) [36]. The ovarian cancer phenotype is transmitted as a
dominant trait with 100% penetrance. TgMISIIR-TAg females are
infertile; therefore, mice are propagated by crossing TgMISIIR-TAg
males with wild-type (WT) littermate females.
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Both C57BL/6 C3KO (B6.129S4-C3tm1Crr/J) and C5aRKO
(C5ar1tm1Cge/J) mice are viable and fertile but have impaired im-
mune responses.
To obtain TgMISIIR-TAg transgenic female mice deficient for
C3 (Tg+C3KO) or C5aR (Tg+C5aRKO), we crossed TgMISIIR-TAg
males with C3KO or C5aRKO females. TgMISIIR-TAg males hetero-
zygous for C3 (Tg+C3HET) or C5aR (Tg+C5aRHET) were then crossed
with females homozygous for C3 or C5aR. The litters were sparse
and small (less than or equal to five pups), consistent with an earlier
report describing early pregnancy impairment in C3KO mice [51].
Genotyping was performed by polymerase chain reaction (PCR) using
previously described primers [35,36] (Figure W1, E and F).
Immunohistochemistry and Immunofluorescence
Ovaries and ovarian tumors were collected from 16-week-old mice
and preserved in optimal cutting temperature (OCT)media embedding
(Tissue-Tek; Sakura FinetekUSA, Torrance, CA). Sections (8 μm)were
cut, air-dried for 1 hour at room temperature, and fixed by immersion
in cold 100% acetone for 5 minutes. After two washes in phosphate-
buffered saline (PBS), slides were blocked with goat serum (Vector Labs,
Burlingame, CA). ECs were stained with a rat anti-mouse CD31 mAb
(BD Pharmingen, San Jose, CA) followed by biotinylated polyclonal
goat anti-rat IgG (BD Pharmingen) and detected with the VectaStain
ABC reagent and DAB (Vector Labs). Microvessels were defined as
any dark-stained ECs or cell clusters clearly separated from adjacent
structures, tumor cells, and other connective tissue elements. Micro-
vascular density was expressed as the number of vessels per field of view.
C3 deposition was detected with a rat anti-mouse C3b/iC3b/C3c mAb
(2/11; HyCult) followed by Alexa 488–labeled goat anti-rat anti-IgG1
mAb (Invitrogen). The values reported reflect C3b/iC3b deposition per
cell, averaged from five field-of-view tumors. Adjacent sections were
stained with hematoxylin and eosin for histopathologic evaluation.
Cell Preparation and Antibodies
Ovaries and ovarian tumors from WT, TgMISIIR-TAg, Tg+C3WT,
Tg+C3HET, Tg+C3KO, Tg+C5aRWT, Tg+C5aRHET, and Tg+C5aRKO
mice were collected in ice-cold Dulbecco’s modified Eagle’s medium
supplemented with 10% (vol/vol) FBS and 1% penicillin/streptomycin
and mechanically dissociated using a cell strainer (BD Biosciences,
San Jose, CA). Red blood cells were eliminated with ammonium-
chloride-potassium (ACK) lysing buffer (Gibco, Grand Island, NY).
Freshly isolated single-cell (WT, Tg+C3WT, Tg+C3HET, and Tg+C3KO)
or frozen suspensions (95% FBS and 5% DMSO, stored at −80°C
for up to 4 months; Tg+C5aRWT, Tg+C5aRHET, and Tg+C5aRKO)
were first incubated with rat anti-mouse CD16-CD32 (2.4G2) mAb
to block Fc receptors, and mouse leukocyte labeling was performed by
incubation with fluorochrome-conjugated rat anti-mouse CD3 (17A2),
CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), CD45 (30-F11),
CD45R (B220), CD19 (ID3), F480 (BM8), or Gr-1 (RB6-8C5) Abs, at
4°C for 30 minutes. Isotype-matched antibodies were used as nega-
tive controls. For intracellular analysis of cytokines, cells were permeabil-
ized with Cytofix/Cytoperm and Perm/Wash buffers (BD Biosciences)
and stained with fluorochrome-conjugated rat anti-mouse interleukin-10
(IL-10), IL-12 (p40/p70), interferon-gamma (IFN-γ), or FoxP3 (FJK-16a)
Abs. All Abs were purchased from BD Biosciences.
For intracellular analysis of cytokines, single-cell suspensions of
whole mouse tumor (5 × 106) were first cultured for 24 hours at
37°C in 5% CO2. Cells were then resuspended in fresh medium with
0.002% 2-β-mercaptoethanol (Sigma, St Louis, MO) for 4 hours in
5% CO2. In some cases, cells were stimulated with lipopolysaccharide
(LPS; 1 μg/ml) and IFN-γ (10 ng/ml) plus monensin (4 μl/6 ml of cell
culture). For T-cell activation, 20 μl of anti-CD3/anti-CD28 activation
beads were added per milliliter of culture as recommended by the
manufacturer (Miltenyi, Auburn, CA).
In Vivo Angiogenic Assays
Growth factor–reduced Matrigel was mixed at 4°C (liquid state) at a
1:1 ratio with 10 ng/ml VEGF-A human recombinant homodimer pro-
tein (Millipore, Billerica, MA) or PBS as negative control. C57BL/6
WTmice were injected with 100 μl of each mixture in the right and left
flanks. Animals were sacrificed 2weeks after injection.Matrigel plugs were
excised and digested with 1 mg/ml collagenase II and 10,000 U/ml
DNAse I (Sigma) for 30 minutes at room temperature, as described
[52], then resuspended in PBS and analyzed by flow cytometry for
the expression of CD31 and CD144.
Tube Formation
Tube formation assays measure the ability of ECs to form capillary-
like tubes. Human mammary epithelial cells (HMECs; 2 × 106) at pas-
sages 2 to 6 were cultured in a T75 cm2 flask in HMEC medium
[MDCB131 medium (Gibco) supplemented with 10% (vol/vol)
FBS, 1% penicillin/streptomycin, 100 μg/ml endothelial cell growth
supplement (ECGS), and heparin (Sigma)]. The following day, cells
were starved for 1 hour in MDCB131 medium and then harvested,
and 2 × 105 cells/well were incubated in Matrigel 24-well plates (BD)
with 2 nMC5a native protein or human recombinant proteinsVEGF-A
(VEGF165 homodimer) at 2 ng/ml, VEGF165 single domain (35.0MWt,
Peprotech, RockyHill, NJ) at 2 ng/ml (57 nM) or 2.7 ng/ml (77 nM), or
VEGF121 single domain (25.4 MWt, Peprotech) at 2 ng/ml (78 nM),
in the presence or absence of 100 × PMX53 (AcF[OPdChaWR]) or of a
chemically similar control peptide (AcF[OPdChaA(d)R]) that lacks
functional properties. Plates were incubated at 37°C for 4 hours and
endothelial tube formation was examined using a light microscope
(Nikon, Melville, NY) at ×10 magnification. Tube formation per area
was analyzed using ImagePro software (Media Cybernetics, Rockville,
MD). Experiments were repeated three times.
VEGF Isoform-specific Reverse Transcription–PCR
RNAs were extracted using Trizol reagent from 2 × 105 HMECs or
from single-cell suspension of mouse organs. HMECs were cultured
at 2 × 105 cells/well in HMEC medium alone or supplemented with
C5a native protein (10,400 MWt, CompTech, Tyler, TX) at 2 nM
(20.8 ng/ml), and/or VEGF-A (1 ng/ml), with or without PMX53
C5a inhibitor or PMX53 control peptide in 12-well plates for 24 hours.
Mouse spleen, liver, and bone marrow tissues were collected from
C57BL/6, C3KO, orC5aRKOmice.mRNAswere reverse transcribed using
M-MLV Reverse Transcriptase (Promega, Madison, WI). Human and
mouse VEGFs, human β2-microglobulin, and mouse glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primers and PCR conditions
were used as described [53]. Densitometry analysis was performed
using ImageJ software (Image processing and analysis in Java) freely
available from the National Institutes of Health at http://rsb.info.nih.
gov/ij. Experiments were repeated three times.
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Statistical Analyses
The data from experiments with two groups were analyzed using
Student’s t test and data from experiments with more than two
groups were analyzed using one-way analysis of variance (ANOVA)
using Satterthwaite and Welch adjustments for unequal variances,
respectively. RNA expression and percentages of cells by type were
transformed using the natural logarithm before their analysis. When
the ANOVA was significant, pairwise comparisons were evaluated
using Tukey procedure. Statistical significance was reached at P < .05.
Analyses were performed using SAS software, version 9.2 (SAS Institute,
Inc, Wayne, PA).
Results
Genetic C3 Deficiency Impairs Ovarian Tumor
Development and Growth
In a transplanted tumor model, we have previously characterized
the spontaneous activation of complement in the tumor vasculature
and stroma, as evidenced by tumor-specific deposition of the C3 cleav-
age products C3b/iC3b in tumor-bearing mice [16]. To determine
whether complement also plays a role during early spontaneous tumor
formation, we crossed C3KO mice with TgMISIIR-TAg transgenic
mice to obtain Tg+C3KO mice. Although tumor development in the
TgMISIIR-TAg model is stochastic, longitudinal in vivo imaging and
quantitative tumor growth analyses demonstrated that TgMISIIR-
TAg ovarian tumors are apparent by immunohistochemical staining
as early as 4 weeks; ovaries exhibit enlargement by 13 weeks with
a doubling time of 7.3 days [37,38], and by 16 weeks, all mice de-
velop solid tumors that consistently reach 0.7 ± 0.2 cm3 in volume.
TgMISIIR-TAg tumors are frequently accompanied by peritoneal
dissemination and ascites, and the average life span of these mice
is ∼22 weeks [37]. Given the central role of C3 in the complement
cascade, we hypothesized that Tg+C3KO mice would be unable to
generate complement effectors downstream of C3.
We compared tumor development of 16-week-old female littermates
heterozygous for the TAg transgene and WT (Tg+C3WT), heterozygous
(Tg+C3HET), or deficient (Tg+C3KO) for C3. All Tg+C3WT mice devel-
oped bilateral ovarian tumors. In contrast, 9 of 12 ovaries of Tg+C3KO
mice were histologically normal (Figure 1A) with no visible micro-
scopic tumors (Figure W1). In addition, tumors that developed
in Tg+C3KO and Tg+C3HET mice were significantly smaller than
Tg+C3WT tumors (both P ≤ .001), while Tg+C3KO and Tg+C3HET
tumor volumes were not significantly different from each other
(P = .279) (Figure 1A). Tg+C3KO mice were unable to produce
Figure 1. Genetic complement deficiency impairs SV40+ ovarian tumor growth and development. (A) Tumors were collected from 16-week-
old Tg+C3WT, Tg+C3HET, and Tg+C3KO mice and measured with calipers. Volumes were calculated using the mathematical formula for
the volume of an ellipsoid: V = 4/3(3.1416)abc, where a, b, and c represent the semi-axes of each diameter. P < .05. (B) Confocal micros-
copy of frozen tumor sections labeled with anti-C3b/iC3b/C3c antibody and 4′,6′-diamino-2-phenylindole (DAPI). Original magnification, ×23.
Results are representative of four Tg+C3WT tumors, four Tg+C3HET tumors, and two Tg+C3KO tumors. (C) Quantification of C3b/iC3b/C3c
deposition on tumor cells from 16-week-old Tg+C3WT, Tg+C3HET, and Tg+C3KOmice (n/group = 5). Bars represent means ± standard error.
(D) Cell composition of ovarian tumors in Tg+C3WT (n=3), Tg+C3HET (n=5), and Tg+C3KO (n=3)mice by flow cytometry. Tumor cells were
identified by staining with anti-SV40 Ab and tumor-infiltrating leukocytes with anti-CD45 Ab.
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the convertases required for the generation of complement effectors
downstream of C3 because of complement deficiency, and the deposi-
tion of iC3b was attenuated in heterozygous mice (Tg+C3HET) when
compared to littermates with intact complement (Tg+C3WT) (Figure 1,
B andC). These results indicate that complement activation is critical for
ovarian tumor establishment and growth.
C3 Deficiency Is Associated with Dampened Cellular
Effector Mechanisms
The composition of tumor-infiltrating leukocytes was analyzed as a
possible explanation for decreased or absent tumor growth in Tg+C3HET
and Tg+C3KOmice. No difference in the percentages of tumor-infiltrating
leukocytes were observed across the groups (Figure 1D, P = .355). Due
Figure 2. Functional impairment of tumor-immune infiltrate in Tg+C3HET mice. (A) Ovarian tumors from 16-week-old Tg+C3WT mice
(black bars; n = 4) and Tg+C3HET mice (gray bars; n = 4) were dissociated and stained for CD45, CD11b, B220, F480, GR1, CD3, CD8,
CD4, CD25, and FoxP3. CD45+ leukocytes were gated and macrophages were identified as CD11b+F480+, B cells as CD11b−B220+ cells,
MDSCs as CD11b+GR1+, CD8+ T cells as CD3+CD8+ cells, and regulatory T cells as CD4+CD25+FoxP3+. Bars represent percentages
of CD45+ cells ± standard error. (B–E) Ovarian tumors were collected from 16-week-old Tg+C3WT (n = 4) and Tg+C3HET (n = 4) mice,
mechanically dissociated to a single-cell suspension and incubated 4 hours in medium only (white bars), or activated for 4 hours with
LPS and IFN-γ (black bars), or with anti-CD3 and anti-CD28 mAbs (gray bars). Cells were then stained for CD45, F480, and CD11b (macro-
phages) (B, C), CD45 and B220 (B cells) (D), or CD45, CD3, and CD8 (T cells) (E), washed and permeabilized for intracellular staining for
IL-12 (B), IL-10 (C, D), or IFN-γ (E). Bars represent mean percentages ± standard errors.
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to the fact that Tg+C3KO mice bore no, or only very small, ovarian
tumors with a sparse amount of tumor cell infiltrates (Figure 1D), we
focused the rest of our studies on Tg+C3WT and Tg+C3HET tumor–
infiltrating leukocytes. No significant differences in the frequency of
tumor-infiltrating macrophages, B cells, and MDSCs were found
between Tg+C3WT and Tg+C3HET groups at 16 weeks of age. How-
ever, Tg+C3HET tumor infiltrates contained more CD8+ T cells (P <
.0001) and less FoxP3+CD4+ T cells (P = .029) than Tg+C3WT tumor
infiltrates (Figure 2A).
Macrophages and T and B cells from Tg+C3HET and Tg+C3WT
littermates were then functionally characterized by flow cytometry.
In the absence of stimulation (Figure 2, B–E , white bars), no dif-
ference were noticed among the two groups in the percentages
of macrophages expressing IL-12 (Figure 2B, P = .948) or IL-10
(Figure 2C , P = .447), of B cells expressing IL-10 (Figure 2D, P =
.092), or of CD8+ T cells expressing IFN-γ (Figure 2E , P = .765).
However, after a short stimulation with LPS and IFN-γ (Figure 2,
B–D, black bars) or with anti-CD3 and anti-CD28 (Figure 2E ,
gray bars), the percentages of macrophages producing IL-12 (Fig-
ure 2B, P = .034) or IL-10 (Figure 2C , P = .001), of B cells produc-
ing IL-10 (Figure 2D, P = .0043), or of T cells producing IFN-γ
(Figure 2E , P = .0038) were significantly lower in Tg+C3HET mice
than in Tg+C3WT mice. We thus concluded that C3 deficiency
was associated with dampened cellular effector mechanisms in the
ovarian tumor microenvironment. This suggested that alternate mecha-
nisms besides cell-mediated immune rejection were likely mainly re-
sponsible for the decrease in tumor incidence and growth observed in
Tg+C3KO mice.
Genetic C3 Deficiency Impairs Tumor Vascularization
and In Vivo EC Function
In preclinical models of AMD, deficiencies of C3a or C5a receptors
result in decreased choroidal neovascularization and VEGF levels.
Similar observations were reported when WT mice were treated with
C3aR and C5aR antagonists, or neutralizing antibodies against C3a
and C5a [21], suggesting an important role for complement in modu-
lating vascularization. In humans, the number of chronically activated
tumor-infiltrating innate immune cells is positively correlated with
blood vessel density [54], while the attenuation of innate immunity
in premalignant tissues reduces angiogenesis and limits tumor devel-
opment in murine models [55]. We therefore asked whether defective
angiogenesis was responsible for the reduced tumor formation in
our model. Tumor microvascular density (MVD) was assessed by
CD31 staining and quantification of vessel number in Tg+C3HET
and Tg+C3WT littermates. MVD was significantly decreased in tu-
mors from Tg+C3HET littermates (Figure 3A, P = .023), suggesting a
functional role of complement for ECs. To address whether genetic
Figure 3. Genetic complement deficiency impairs neo-angiogenesis. (A) Tumor microvasculature was evaluated by CD31 staining (dark
blue staining) of frozen tumor sections from 16-week-old Tg+C3WT and Tg+C3HET mice. Values reflect the number of CD31+ vessels aver-
aged from five high-power fields per slide permouse. Original magnification, ×10. Bars representmeans of CD31+microvessels± standard
error. (B–D) Bars represent the absolute number of total cells (B), or CD31+ ECs (C), or the ratios of CD31+ ECs and total cells (D) attracted
to Matrigel plugs admixed with recombinant VEGF (10 ng/ml) and implanted in C57BL/6 mice (WT, gray bar, n/group = 5) or C3KO mice
(black bar, n/group = 5) ± standard error.
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complement deficiency could alter in vivo angiogenesis, we compared
the in vivo colonization of Matrigel plugs admixed with VEGF in
WT and C3KO mice. The numbers of total cells infiltrating VEGF–
Matrigel plugs after 2 weeks were significantly reduced in C3KO mice
compared to WT mice (Figure 3B, P = .0012), as was the number of
CD31+ ECs (Figure 3C , P < .0001). However, the ratios of CD31+
ECs versus total cells were not significantly different in WT and C3KO
mouse VEGF–Matrigel plugs (Figure 3D, P = .149). These results
Figure 4. Pharmacological inhibition of C5aR targets the VEGF165 isoform. (A) Representative pictures of tube formation. Human micro-
vascular ECs (2 × 105) were seeded onto Matrigel and cultured in MCDB-131 culture medium supplemented with ECGS/heparin and
2 ng/ml of either VEGF-A (1, 6, 11), VEGF165 (2, 7, 12), or VEGF121 (3, 8, 13), or 2 nM C5a (4, 9, 14) in the presence of 200 ng/ml PMX53
(6–10) or PMX53 control peptide (Ctl peptide, 11–15). As negative controls, cells were cultured with medium supplemented with ECGS/
heparin only (5, 10, 15). Tube formation was assayed after 4 hours by phase contrast microscopy and analyzed by measuring tube
length per area using the ImagePro software. (B, C) Measures of tube formation of four fields per treatment (B) with 2 ng/ml VEGF-A,
VEGF165, or VEGF121 or (C) with equimolar concentrations of VEGF165 (2.7 ng/ml) and/or VEGF121 (2 ng/ml). Bars represent means ±
standard error from two independent experiments. (D) Representative picture of PCR amplification of VEGF isoform in the presence or
absence of C5a, VEGF-A, and/or PMX53 (as indicated). PCR amplification of β2-microglobulin was used as a control. (E, F) Densitometric
analysis of transcript expression of VEFG165 (E) and VEFG121 (F) isoforms in HMECs treated with 2 nM C5a (black bars) or 2 ng/ml VEGF-A
(gray bars) in medium or in the presence of 200 ng/ml PMX53 or control peptide (as indicated). VEGF isoform values were normalized to
those of β2-microglobulin. Bars represent mean ± standard error from five independent experiments.
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supported the hypothesis that genetic C3 heterogeneity or deficiency
impairs EC effector mechanisms in our model.
Pharmacological Inhibition of Complement Impairs
VEGF165-dependent Function of Human ECs
To assess whether our in vivo findings were relevant to human
physiology, we sought to study the effects of complement pharmaco-
logical inhibition on the human EC line HMEC. The C5aR is ex-
pressed on ECs and upregulated during inflammation [56,57]. C5aR
function can be inhibited by PMX53, a peptide that has been used
in preclinical models to block neutrophil chemotaxis and clinically
for treatment of rheumatoid arthritis and psoriasis [58]. We studied
the effects of PMX53-mediated inhibition of C5aR on HMEC tube
formation stimulated by VEGF-A (Figure 4, A1 and B1, white bar)
and the commercially available isoforms VEGF165 (Figure 4, A2 and
B2, white bar) and VEGF121 (Figure 4, A3 and B3, white bar) compared
to a control peptide (Figure 4, A11–15 and B, gray bars). PMX53
(Figure 4B, black bars) impaired VEGF165-mediated tube formation
(Figure 4,A7,B2, andC ) but not VEGF121-mediated tube formation (Fig-
ure 4,A8, B3, andC , ANOVA P > .05). PMX53 also impaired HMEC
tube formation mediated by equimolar concentrations of VEGF165
and VEGF121 (Figure 4C , P = .0232). As expected, treatment with
control peptide did not affect tube formation. Of note, the difference
observed between ECs activated by VEGF-A and treated with PMX53
was statistically significant but not meaningful (Figure 4, A6 and
B1, P = .0127 for VEGF-A vs VEGF-A/PMX53 but P = .9368 for
VEGF-A/PMX53 vsVEGF-A/control peptide). These results suggested
that C5aR inhibition selectively affected tube formation mediated by
the VEGF165 isoform.
C5a Promotes Tube Formation in a
VEGF165-dependent Manner
To determine whether C5a had direct functional effects on ECs,
HMECs were incubated with native C5a protein at 2 nM (20.8 ng/ml),
which is within the plasma concentration range of C5a degradation
product C5adesArg [59]. Tube formation similar to that mediated by
VEGF-A and VEGF isoforms was observed (Figure 4, A4 and B4,
white bar), while PMX53 inhibited C5a-mediated tube formation
(Figure 4, A9 and B4, black bar, P < .0001). In addition, we found
that PMX53 specifically inhibited the transcription of VEGF165 (Fig-
ure 4, D–E , P = .050) but not of VEGF121 in C5a-treated HMEC
cells (Figure 4, D and F , P = .202). These results suggested a novel
role for C5a in promoting EC tube formation through enhancing
expression of VEGF165.
Genetic C3 Deficiency Affects the Expression of
VEGF164 Isoform
As experimental evidence pointed toward a role for C5a in VEGF165-
mediated activation of human ECs, we performed a comparative analy-
sis of the expression of VEGF isoforms in mice that are complement
deficient or complement sufficient. We analyzed the expression of the
mouse homologues of human VEGF121 and VEGF165 that are mouse
isoforms VEGF120 and VEGF164, respectively, in the spleens, livers,
and bone marrows isolated from WT and C3KO mice. Figure 5 repre-
sents the relative expression of VEGF isoforms in WT and C3KO mice
after normalization against GAPDH. The expression of VEGF164, but
not of VEGF120, was significantly reduced in C3KO livers compared
to WT livers (Figure 5A, P = .048 and Figure 5B, P = .404).
Genetic C5aR Deficiency Impairs Tumor Growth and
Neo-angiogenesis but Not Tumor Immune Infiltrate
To further assess the role of the C5a complement anaphylatoxin
in ovarian cancer progression and angiogenesis, we crossed C5aRKO
mice [35] with C57BL/6 TgMISIIR-TAg transgenic mice. We com-
pared tumor development in 16-week-old female littermates hetero-
zygous for the TAg transgene and C5aR sufficient (Tg+C5aRWT),
C5aR heterozygous (Tg+C5aRHET), or C5aR deficient (Tg+C5aRKO).
While Tg+C5aRWT and Tg+C5aRHET mice developed unilateral
ovarian tumors, three of six ovaries of Tg+C5aRKO mice were histo-
logically normal and Tg+C5aRKO tumors were significantly smaller
than Tg+C5aRWT and Tg+C5aRHET tumors (Figure 6A, P = .001 and
P = .002, respectively). In contrast with C3 deficiency, no difference
in tumor sizes was observed between Tg+C5aRWT and Tg+C5aRHET
mice (Figure 6A, P = .945), and no significant differences were found
across the groups regarding tumor immune infiltrate (Figure 6B, all
ANOVA P > .05). However, as seen in Tg+C3HET mice, tumor MVD
was significantly decreased in tumors from Tg+C5aRHET mice as well
as Tg+C5aRKO mice compared to Tg+C5aRWT littermates (Figure 6C ,
P = .0004 and P < .0001, respectively). Additionally, MVD in tumors
from Tg+C5aRKO mice was significantly decreased compared to
Tg+C5aRHET mice (Figure 6C , P < .0001). Finally, in vivo assays
showed significantly impaired angiogenesis in C5aRKO mice compared
to WT mice (Figure 6D, P = .019). Collectively, these results supported
the hypothesis that the tumor growth inhibition observed in mice with
Figure 5. Altered expression of VEGF164 isoform in complement-
deficient mice. Densitometry analysis of expression of mouse
VEFG164 (A) and VEFG120 (B) isoforms in WT versus C3
KO spleens,
livers, and bone marrows (as indicated). VEGF isoform values were
normalized to those of GAPDH. Bars display mean ± standard error
from three different mice per group.
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genetic complement deficiencies was associated with the alteration of
EC function.
Discussion
Cancer establishment and progression is a multistep process of cu-
mulative genetic alterations that enable cells to acquire uncontrolled
growth. It has recently become clear, however, that to initiate cancer
growth, genetically induced cell autonomy is often not sufficient, and
an inflammatory reaction of the underlying stroma is required. The
idea that chronic inflammation is intimately related to malignant
transformation and tumor progression has been substantiated by hu-
man epidemiologic data and genetic experiments in mice, but the
molecular and cellular determinants of these processes have not been
well characterized. Here, we showed that deficiency of C3 or C5aR
dramatically attenuates the tumor phenotype, abrogating tumor
establishment and progression. Thus, complement activation is a crit-
ical component of the inflammatory process that supports oncogene-
driven carcinogenesis. However, complement inactivation did not
reduce the inflammatory infiltrate in tumors; we found no difference
in the percentage of tumor-infiltrating leukocytes in Tg+C3HET when
compared to Tg+C3WT, with the exception of CD8+ T cells and
CD4+ FoxP3+ T cells. This suggests that, contrary to the acute in-
flammation process in which complement anaphylatoxins likely
play a major role in orchestrating the inflammatory infiltrate, other
factors, such as chemokines produced by tumor and stromal cells,
recruit copious amounts of leukocytes to tumors, even in the absence
of complement activation. The presence of more tumor-infiltrating
effector T cells and less regulatory T cells in Tg+C3HET compared to
Tg+C3WT was in agreement with our previous findings in a mouse
model of subcutaneous TC-1 cervical cancer, in which impaired growth
of tumor cells was found when C5aR was blocked by an antagonist
peptide [16]; this effect was attributed to enhanced CD8+ T-cell infil-
tration in tumors and reduced recruitment of MDSCs [16]. Further-
more, we found no evidence for immune cell activation in Tg+C3HET
tumors but rather a general suppression of leukocyte function, includ-
ing a global reduction of cytokine production in Tg+C3HET mice when
compared to those fully sufficient in C3. These findings thus showed
only indirect evidence of immune-mediated tumor rejection in these
mice, through the decrease of immune regulatory cells or cytokines.
Likewise, no evidence of immune-mediated tumor rejection was found
in C5aR-hemizygous or C5aR-deficient mice, despite the dramatic
attenuation of the tumor phenotype. The lower percentage of tumor-
infiltrating CD4+FoxP3+ T cells in Tg+C3HET tumors could explain
why the Tg+C3HET mice, but not the Tg+C5aRHET mice, developed
smaller tumors than their WT littermates. However, this finding was
Figure 6. Genetic C5aR deficiency also impairs ovarian cancer growth and vascularization but not tumor immune infiltrate. (A) Tumors
were collected from 16-week-old Tg+C5aRWT (n = 4), Tg+C5aRHET (n = 4), and Tg+C5aRKO mice (n = 3) and measured with calipers.
Volumes were calculated using the mathematical formula for the volume of an ellipsoid: V = 4/3(3.1416)abc, where a, b, and c represent
the semi-axes of each diameter. (B) Comparative composition of tumor-infiltrating leukocyte function in Tg+C5aRWT, Tg+C5aRHET, and
Tg+C5aRKO mice. Ovarian tumors from 16-week-old Tg+C5aRWT mice (black bars, n = 3), Tg+C5aRHET mice (gray bars, n = 3), and
Tg+C5aRKO mice (white bars, n= 3) were dissociated and stained as described in Figure 2A. Bars represent mean percentages ± standard
errors. (C) Tumor microvasculature was evaluated by CD31 staining and immunohistochemistry (IHC) (dark brown staining) of tumors from
16-week-old Tg+C5aRWT, Tg+C5aRHET, and Tg+C5aRKO mice. Values reflect the number of CD31+ vessels averaged from five high-power
fields per slide per mouse. Original magnification, ×10. Bars represent means of CD31+ microvessels ± standard errors from at least four
tumors per group. (D) Bars represent CD31+ECsattracted toMatrigel plugsadmixedwith VEGF (10ng/ml) in C57BL/6mice (WT) (n/group=5)
or C5aRKO mice (n/group = 5) ± standard error.
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not sufficient to explain the dramatic phenotype of Tg+C5aRKO mice
where no change in tumor-infiltrating CD4+FoxP3+ T cells was found.
Thus, while our data support the notion that complement activation
plays a critical role in activating tumor-infiltrating leukocytes, a process
that is apparently essential to their tumor-promoting function, our data
also indicate that increased activation of effector cells is not the
major mechanism leading to suppressed ovarian oncogenesis in C3-
hemizygous and C5aR-hemizygous or C5aR-deficient mice, and there
is likely an alternate mechanism of tumor inhibition.
Because tumor-induced angiogenesis is largely dependent on VEGF,
VEGF-neutralizing drugs are actively sought to inhibit cancer growth.
Current VEGF-neutralizing agents inhibit tumor angiogenesis by
blocking activation of VEGF receptors [60], but agents have already
been developed to selectively target VEGF isoforms. For example,
Pegaptanib targets VEGF165 for the treatment of AMD [61], and
the specific targeting of VEGF isoforms has been proposed as an
effective cancer therapy [62]. We show here that the complement
anaphylatoxin C5a present in the inflammatory milieu activates ECs
and that the pharmacological inhibition of C5aR specifically targets
the VEGF165 isoform. Our results reveal a previously unknown
role for complement activation in ovarian tumor vascularization and
growth. However, these data should be considered within the context
of our ovarian tumor model. While another study has shown that
lack of C3 results in increased angiogenesis in a model of retinopathy
of prematurity [63], here it was found that C5a stimulation of ECs
mediates angiogenic activity. Thus, the specific pathology may deter-
mine how complement influences different cell types, as well as the
outcomes of that influence. The fact that small, unilateral ovarian
tumors were present in 3 of 12 Tg+C3KO mouse ovaries might be
due to phenotype variability or incomplete penetrance not related to
variations in genetic background or levels in gene expression [64,65].
Because C3KO mice produce C3 transcript and some of it can be
translated into an inactive pro-form of C3 protein, one cannot elimi-
nate the possibility that some active C3 can be produced in the
Tg+C3KO mice through alternate splicing or processing. Alternatively,
some unrelated factors could have also been differentially activated
in these mice, such as the tumor microenvironment, or a different
microbiome that could affect factors related to tumor growth, or even
epigenetics. Future studies are needed to determine the molecular
mechanisms underlying Tg+C3KO phenotype variability.
In conclusion, our findings have important implications for our
understanding of the mechanisms underlying ovarian cancer de-
velopment and for the design of future preventive and therapeutic
strategies, such as combination therapies associating complement
inhibitors with targeted anti-angiogenic therapeutic agents for the
treatment of ovarian cancer.
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Figure W1. Characterization of mice with genetic complement deficiencies. (A–D) Hematoxylin and eosin–stained frozen sections from
ovaries of 16-week-old Tg+C3WT (A) and Tg+C3KO (B–D) mice. Results are representative of 19 Tg+C3WT ovaries and 12 Tg+C3KO ovaries.
Stars indicate oocytes. GC, granulosa cells; CL, corpus luteum; T, tumor cells. Original magnification, ×4. (E, F) Genotyping was performed
by PCR on genomic DNA using conditions and primers previously described by Connolly and colleagues to detect the insertion of MISIIR
(773 bp) and by the Jackson Laboratory to detect intact C3 (350 bp), C3 deficiency (280 bp), intact C5aR (386 bp), and C5aR deficiency
(244bp). (E) 1) Tg−C3KO; 2) Tg+C3HET; 3) Tg−C3KO; 4) Tg+C5aR
WT; 5) Tg−C5aR
HET; 6) Tg−C5a
KO. (F) 1) Tg−C5aRWT; 2) Tg−C5aRHET; 3) Tg−C5aRKO;
4) Tg+C5aR
WT; 5) Tg−C5aR
HET; 6) Tg−C5aR
KO.
